← All trials
NCT06607263
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Sep 23, 2024
- Last posted
- Sep 23, 2024
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Colgate PalmoliveLead sponsor
- Federal University of Rio Grande do SulOfficial
- Federal University of Rio Grande do SulCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.